Marius Pharma and Numan Team Up to Address Testosterone Deficiency with KYZATREX® Capsules

RALEIGH, N.C., Sept. 18, 2024 – Marius Pharmaceuticals has entered into a new partnership with Numan, a UK-based digital health platform, to introduce KYZATREX® (testosterone undecanoate) CIII capsules into Numan’s range of products. KYZATREX, approved by the FDA in the US, is intended for adult men with low or no testosterone due to specific medical conditions. This collaboration represents a vital advancement in addressing testosterone deficiency by providing a more thorough and patient-centric solution.

Testosterone deficiency (TD) is increasingly recognized as a global health issue. It affects approximately 40% of men over 45 years old and 30-50% of men who are obese or have type 2 diabetes, according to the Endocrine Society. In the UK alone, an estimated 3 million men suffer from TD, with around 90% of cases remaining untreated. TD has a bi-directional relationship with metabolic diseases and early research indicates it may contribute to conditions like depression and inflammatory diseases. As these health challenges continue to rise, the collaboration between Marius Pharmaceuticals and Numan positions KYZATREX as a promising treatment option for this widespread condition.

Amit Shah, Chief Operating Officer at Marius, expressed enthusiasm about the partnership with Numan. "We are thrilled to partner with Numan and expand the availability of KYZATREX to patients in the UK. Testosterone deficiency is a global health issue, and our collaboration allows us to offer men a therapy that is not only effective but also designed with patient safety in mind. By joining forces with a trusted health platform like Numan, we’re confident that more men will have access to the care they need to improve their overall health and well-being."

KYZATREX is designed to be easy on the body by bypassing the liver, which prevents potential liver damage—a common issue with other forms of testosterone therapy. In a six-month clinical trial involving 139 men with low testosterone, 88% of KYZATREX patients achieved normal testosterone levels by Day 90. For patients who completed the study (n=127), this figure rose to 96%. Additionally, KYZATREX patients saw a twofold increase in Free Testosterone levels and a 30% reduction in Sex Hormone Binding Globulin (SHBG) levels.

Numan, a leader in the medical weight loss sector in the UK, brings a patient-focused approach to testosterone therapy. Their process involves a holistic, guideline-led diagnosis using gold-standard blood testing and expert analysis. By incorporating KYZATREX into their offerings, Numan continues to enhance its commitment to men’s health, providing tailored treatment programs that target the root causes of testosterone deficiency and support overall well-being.

About Marius Pharmaceuticals

Marius Pharmaceuticals is dedicated to improving patients' lives by focusing on therapies for hypogonadism or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and reduce unnecessary costs to the global healthcare system.

About KYZATREX® (Testosterone Undecanoate)

KYZATREX is a proprietary softgel oral formulation absorbed mainly through the lymphatic system, making it non-toxic to the liver. It is indicated for adult males with conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX were confirmed in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males aged 18 to 65 with documented hypogonadism. In the efficacy population (n=139), 88% of men treated with KYZATREX achieved a mean plasma total testosterone concentration within the normal range on the final pharmacokinetic visit of the study at Day 90. Patients reported improvements in symptoms of low testosterone, including quality of life, energy, erectile function, sexual intercourse, and mood. The most common side effect, reported in over 2% of patients, was increased blood pressure.

For additional information on KYZATREX’s safety and proper usage, patients are encouraged to speak with their healthcare provider.